viernes, 30 de agosto de 2019

Biotech completed a round trip 2019

The Readout
Damian Garde

Biotech completed a round trip 2019

3c3c03eb-ead2-4257-b1a7-8430ed411081.png
As The Wall Street Journal’s Charley Grant pointed out, the much-watched XBI biotech index is basically where it was back at the J.P. Morgan Health Care Conference in January. The year began with a runup tied to Bristol-Myers Squibb’s $74 billion offer for Celgene, but the XBI has since given back all of its subsequent gains.

What’s notable is that the stuff that usually drives biotech stocks upward — big acquisitions and successful clinical trials — has been abundant in 2019. AbbVie is paying $63 billion for Allergan. Novartis developed a particularly effective gene therapy. Targeted cancer drugs are having a renaissance.

And yet here the sector sits, no better than it was eight months ago.

No hay comentarios:

Publicar un comentario